Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

被引:0
作者
Archana Anantharaman
Terence Friedlander
David Lu
Rachel Krupa
Gayatri Premasekharan
Jeffrey Hough
Matthew Edwards
Rosa Paz
Karla Lindquist
Ryon Graf
Adam Jendrisak
Jessica Louw
Lyndsey Dugan
Sarah Baird
Yipeng Wang
Ryan Dittamore
Pamela L. Paris
机构
[1] University of California at San Francisco,Division of Hematology
[2] Epic Sciences,Oncology, Helen Diller Family Comprehensive Cancer Center
[3] University of California at San Francisco,Department of Urology, Helen Diller Family Comprehensive Cancer Center
来源
BMC Cancer | / 16卷
关键词
Circulating tumor cells; PD-L1; Bladder cancer; Liquid biopsy; Biomarkers;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 518 条
  • [1] Ploeg M(2009)The present and future burden of urinary bladder cancer in the world World J Urol 27 289-293
  • [2] Aben KK(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29
  • [3] Kiemeney LA(2012)Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 J Clin Oncol 30 1107-1113
  • [4] Siegel R(2006)Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 50-54
  • [5] Ma J(2000)Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 3068-3077
  • [6] Zou Z(2011)International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2171-2177
  • [7] Jemal A(2014)MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 558-562
  • [8] Bellmunt J(2013)A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat Immunol 14 1212-1218
  • [9] von der Maase H(2014)Programmed death-1 pathway in cancer and autoimmunity Clin Immunol 153 145-152
  • [10] Mead GM(2014)Orchestrating immune check-point blockade for cancer immunotherapy in combinations Curr Opin Immunol 27 89-97